Stephen Kraus, a partner in the Cambridge, Mass. office, has worked with Bessemer since 2004 and focuses on the healthcare sector.
Currently, he focuses his new deal activity on early and growth stage opportunities in healthcare IT and healthcare services. He currently sits on the boards of Liazon, Health Essentials, DocuTAP, Ovascience, Verastem, Allena Pharmaceuticals and Alcresta and is actively involved in BVP's investments in Acceleron and Proteon.
Steve has been actively involved in Bessemer’s investments in Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ: AFFY); Aveo (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec, Verastem (NASDAQ: VSTM), and Restore Medical (NASDAQ: REST), acquired by Medtronic.
Prior to joining Bessemer, Steve was a director at the Ironwood Equity Fund, a growth-stage,... See More